A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects

The adoptive transfer of anti-CD19 chimeric antigen receptor (CAR)-engineered T cells has shown impressive clinical responses in patients with refractory B-cell malignancies(1–7). However, the therapeutic effects of CAR-T cells targeting other malignancies have not yet resulted in significant clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kagoya, Yuki, Tanaka, Shinya, Guo, Tingxi, Anczurowski, Mark, Wang, Chung-Hsi, Saso, Kayoko, Butler, Marcus O., Minden, Mark D., Hirano, Naoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839992/
https://www.ncbi.nlm.nih.gov/pubmed/29400710
http://dx.doi.org/10.1038/nm.4478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839992/
https://www.ncbi.nlm.nih.gov/pubmed/29400710
http://dx.doi.org/10.1038/nm.4478

Ejemplares similares